(NASDAQ:ARGX), NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether argenx and certain of its officers and/or directors have engaged […]
(NYSE:KBR), NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of KBR, Inc. (“KBR” or the “Company”) (NYSE: KBR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether KBR and certain of its officers and/or directors have engaged
(NasdaqGM:ALT), NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Altimmune and certain of its officers and/or directors have engaged
(NASDAQ:LINE), NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Lineage, Inc. (“Lineage” or the “Company”) (NASDAQ: LINE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Lineage and certain of its officers and/or directors have engaged
(NASDAQ:DYN), NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. (“Dyne” or the “Company”) (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Dyne and certain of its officers and/or directors have
(NYSE:DBI), NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Designer Brands Inc. (“Designer Brands” or the “Company”) (NYSE: DBI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Designer Brands and certain of its officers and/or
(NASDAQ:CAPR), NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Capricor and certain of its officers and/or directors have
(NYSE:CTO), NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of CTO Realty Growth, Inc. (“CTO” or the “Company”) (NYSE: CTO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether CTO and certain of its officers and/or directors
(NASDAQ:EWTX), NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”) (NASDAQ: EWTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Edgewise and certain of its officers and/or directors have
(NASDAQ:UNCY), NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Unicycive and certain of its officers and/or directors have